<![CDATA[Breast carcinoma is a biologically and clinically heterogeneous malignancy. Immunohistochemical assessment of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER2), and Ki-67 supports surrogate molecular subtype classification. This study aimed to describe breast carcinoma molecular subtypes according to age, tumor size, histopathological grade, clinical stage, and histopathological type. A descriptive literature review examined publications from 2015 to 2020 identified through PubMed, MEDLINE, ResearchGate, ScienceDirect, World Health Organization, and Indonesian Ministry of Health sources. Searches used terms related to breast carcinoma, molecular subtypes, age, tumor size, staging, and histopathology. Eligible studies were selected using predefined criteria and synthesized qualitatively through a synthesis matrix. Ten studies comprising 13,085 cases were included. Luminal A was the most prevalent subtype in seven studies, luminal B in two, and triple-negative breast cancer in one. HER2 overexpression was the least prevalent subtype in eight studies. Commonly reported age groups were 41–50 and 51–60 years. Tumors measuring 2–5 cm, histopathological grade II, clinical stage II, and invasive breast carcinoma of no special type were frequently reported. Molecular subtype distributions varied across populations, highlighting the importance of considering population characteristics and immunohistochemical classification methods when interpreting findings.]]>
Copyrights © 2026
